Drug Trial Radar · NCT03277248
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)
Last checked: Nov 20, 2026Latest source record: Dec 6, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
545
Actual
Start
Aug 25, 2017
Primary completion
Aug 4, 2020
Study completion Nov 12, 2020
Sponsor
- Lead sponsor
- TG Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Sep 11, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study determines the Annualized Relapse Rate (ARR) in participants with RMS after 96 weeks (approximately 2 years) treatment with intravenous (IV) infusion of ublituximab/oral placebo compared to 14 mg oral teriflunomide/IV placebo.
Conditions
- Relapsing Multiple Sclerosis (RMS)
Interventions
UblituximabBiological
Administered as an IV infusion.
TeriflunomideDrug
Film coated tablets administered orally.
Oral PlaceboDrug
Administered orally.
IV PlaceboDrug
Administered as an IV Infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized Relapse Rate (ARR)Time frame: Up to 96 weeks
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
TG Therapeutics RMS Investigational Trial site
Phoenix, Arizona
TG Therapeutics RMS Investigational Trial Site
Aurora, Colorado
TG Therapeutics RMS Investigational Trial Site
Tampa, Florida
TG Therapeutics RMS Investigational Trial Site
Lexington, Kentucky
TG Therapeutics RMS Investigational Trial Site
Chesterfield, Missouri
TG Therapeutics RMS Investigational Trial Site
Las Vegas, Nevada
TG Therapeutics RMS Investigational Trial Site
Teaneck, New Jersey
TG Therapeutics RMS Investigational Trial Site
Albuquerque, New Mexico
TG Therapeutics RMS Investigational Trial Site
Patchogue, New York
TG Therapeutics RMS Investigational Trial site
Columbus, Ohio
TG Therapeutics RMS Investigational Trial Site
Pittsburgh, Pennsylvania
TG Therapeutics RMS Investigational Trial site
San Antonio, Texas
TG Therapeutics RMS Investigational Trial site
Seattle, Washington
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.